Frontiers in Pharmacology · Nov 16, 2026
A Review of Cancer Therapy-Related Cardiovascular Toxicity: Mechanisms and Pharmacological Management
By Haipeng Song, Ruolin Gong, Quancheng Han et al.
Cancer therapy-related cardiovascular toxicity includes myocardial dysfunction, ischemia, thrombosis, arrhythmias, and immune-mediated myocarditis, with distinct mechanisms across anticancer treatments. This review integrates evidence published primarily from 2023 to October 2026, building on the 2022 European Society of Cardiology cardio-oncology guideline and International Cardio-Oncology Society consensus. We examine drug-specific injury pathways associated with anthracyclines, other conventional cytotoxic agents (fluoropyrimidines, cyclophosphamide, cisplatin, and taxanes), HER2-directed and other targeted therapies, and immune checkpoint inhibitors; thoracic radiotherapy is addressed briefly for mechanistic comparison. We consider how biomarkers, cardiac imaging, and treatment-related risk assessment may inform cardioprotective decisions without equating early abnormalities with established clinical benefit. A critical comparison of recent trials of neurohormonal antagonists, statins, and sodium–glucose cotransporter 2 inhibitors highlights heterogeneous or preliminary findings, reflecting differences in patient selection, intervention timing, and endpoint definitions. We also distinguish emerging molecular targets, pharmacogenomic markers, and artificial intelligence-based prediction from clinically validated interventions. The available evidence supports treatment-specific cardiovascular assessment but remains insufficient to establish the clinical effectiveness of several proposed preventive drugs. Further adequately powered trials should evaluate mechanism-informed, risk-adapted cardioprotection using clinically meaningful cardiovascular outcomes without compromising anticancer efficacy.